Table 2 Overview of eGFR CpG sites selected for optimized MRS.
From: A methylation risk score for chronic kidney disease: a HyperGEN study
Lead author (EWAS N) | CpG | Chr | Gene | Location | MRS weight | Gene function |
|---|---|---|---|---|---|---|
Qiu (181)31 | cg02090160 | 2 | – | shore | − 0.499 | |
cg11098259 | 15 | AQP9 | open sea | 0.501 | Aquaporin, H2O & urea transport, osmotic stress response | |
Chu (4859)16 | cg12116137 | 17 | PRPF8 | open sea | 0.515 | RNA splicing, mRNA processing, proteolysis |
cg17944885 | 19 | ZNF788; ZNF20 | shelf | − 0.484 | Pseudogene; transcription factor binding | |
cg00994936 | 19 | DAZAP1 | island | 0.515 | RNA binding, placental development & spermatogenesis, cell proliferation | |
Schlosser (33,605)20 | *cg02304370 | 3 | PHRF1 | shore | 1.09e−04 | Enables RNA polymerase binding; SLE, preeclampsia, fasting glucose |
*cg04460609 | 2 | LDB2 | open sea | − 1.34e−04 | Transcription complex, embryo development | |
*cg00501876 | 3 | CSRNP1 | shore | − 8.98e−05 | Transcription factor for Wnt signaling; apoptosis | |
*cg04864179 | 7 | IRF5 | shore | − 8.58e−05 | Transcription factor for interferon activity; SLE & IBD |
